[e-drug] id21 Health

E-drug: id21 Health
---------------------------------------------
id21 Health: the new health research reporting service

id21, the internet-based development research reporting service, is
adding an exciting new facility to its current package with the
launch of id21 Health.

The new resource (at www.id21.org/health) provides a searchable
database of concise, easy-to-read summaries of research relevant to
health policy in developing countries. A wide range of subjects are
covered, including health sector reform, maternal and child health,
sexual and reproductive health, disease and disability, and
environmental health. id21 Health also offers this information in a
free email newsletter, id21HealthNews, for those with limited
internet access.

To subscribe to id21HealthNews, send an email to: lyris@lyris.ids.ac.uk with
the message: 'subscribe id21HealthNews'.

The new site builds on the strengths of id21, a respected resource for
policy-makers and practitioners for nearly 4 years. id21 is supported
by the UK Department for International Development, and hosted by the
Institute for Development Studies at the University of Sussex, UK.

id21 Health also aims to stimulate debate on specific health policy
topics through its free publication, Insights Health. The first
issue, due out in March, will focus on non-communicable diseases.
People wishing to subscribe to Insights Health should send us their
name and full postal address by mail, fax or email.

Please email us at id21@ids.ac.uk if you have any questions or
comments. And please forward this message to colleagues who may also
be interested in our service.

Dr. Heidi Brown
  Health Editor
ID21 at the Institute of Development Studies (Charitable Company No. 877338)
University of Sussex
Brighton BN1 9RE, UK
T: +44 (0) 1273 877115
F: +44 (0) 1273 877335
Heidi Brown <H.Brown@ids.ac.uk>
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.